Kairos Pharma Ltd. (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO® (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. This partnership aims to address the significant unmet need for more effective therapies in advanced prostate cancer, particularly for patients who have developed resistance to standard treatments.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. The company previously reported interim Phase 2 data showing median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population, offering a targeted radiation therapy.
The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.
“This collaboration with Bayer represents a significant step forward in our mission to develop therapies that overcome resistance mechanisms in cancer,” said Dr. John Yu, CEO of Kairos Pharma. “By combining ENV-105 with XOFIGO, we hope to improve outcomes for patients with metastatic castration-resistant prostate cancer, a population with limited treatment options.”
For more details, the full press release is available at https://ibn.fm/emSc4. Additional updates on Kairos Pharma can be found at https://ibn.fm/KAPA.
Kairos Pharma, based in Los Angeles, California, is focused on oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, targets CD105, a protein identified as a key driver of resistance and disease relapse. The company is conducting clinical trials for prostate cancer and non-small cell lung cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the FDA or any other foreign regulator.
This collaboration highlights the potential of combining novel immunotherapies with radiopharmaceuticals to tackle resistant cancers. If successful, the combination could change the standard of care for mCRPC patients with bone metastases.
